AGC Biologics

agcbio.com

DGDGS
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners. AGC Biologics is the product of the convergence and integration of Asahi Glass Company (AGC) Life Sciences, CMC Biologics, and BIOMEVA GmbH. Our extensive network spans three continents, with cGMP-compliant facilities in Seattle, WA; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

news image

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More

AGC BIOLOGICS PARTNERS WITH TAKARA BIO TO MANUFACTURE PLASMID DNA VACCINE AGAINST COVID-19

AGC Biologics | May 22, 2020

news image

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine,...

Read More

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

news image

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More

SAIBA AG SELECTS AGC BIOLOGICS TO DEVELOP AND PRODUCE COVID-19 VACCINE

AGC Biologics | June 16, 2020

news image

AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. ...

Read More
news image

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More
news image

AGC BIOLOGICS PARTNERS WITH TAKARA BIO TO MANUFACTURE PLASMID DNA VACCINE AGAINST COVID-19

AGC Biologics | May 22, 2020

AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in the fight against COVID-19 by collaborating on a prophylaxis DNA vaccine,...

Read More
news image

NOVAVAX SELECTS AGC BIOLOGICS TO MANUFACTURE MATRIX-M™ ADJUVANT FOR NOVEL COVID-19 VACCINE

AGC Biologics | June 03, 2020

AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax' coronavirus vaccine candidate, NVX-CoV2373. AGC Biologics will manufacture Matrix-M™, the adjuvant component of the vaccine, in order to enhan...

Read More
news image

SAIBA AG SELECTS AGC BIOLOGICS TO DEVELOP AND PRODUCE COVID-19 VACCINE

AGC Biologics | June 16, 2020

AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. ...

Read More